Suppr超能文献

我们距离胎盘来源的间充质干细胞的临床应用还有多远?

How far are we from the clinical use of placental-derived mesenchymal stem cells?

作者信息

Fierabracci Alessandra, Lazzari Lorenza, Muraca Maurizio, Parolini Ornella

机构信息

Bambino Gesù Children's Hospital, Autoimmunity Laboratory, Immunology and Pharmacotherapy Area , IRCCS, Viale S. Paolo 15, 00146 Rome , Italy +39 06 6859 2656 ; +39 06 6859 2904 ;

出版信息

Expert Opin Biol Ther. 2015 May;15(5):613-7. doi: 10.1517/14712598.2015.1000856. Epub 2015 Jan 5.

Abstract

In recent years, multiple studies have investigated the biology and clinical applications of mesenchymal stem cells (MSCs), trying to define their markers, and elucidate their effects in animal models. MSCs are available from different tissues, and the use of placental-derived MSCs (PMSCs) for treating a variety of disorders is on the forefront. Herein, we discuss the most recent findings regarding the standardization of their isolation procedure and phenotype, along with advantages and limitations of their use. We also discuss the safety of the placental cell products, including the issue of senescence and mutagenesis of PMSCs, and efficacy from preclinical studies.

摘要

近年来,多项研究对间充质干细胞(MSCs)的生物学特性及临床应用进行了调查,试图确定其标志物,并阐明其在动物模型中的作用。MSCs可从不同组织中获取,而使用胎盘来源的间充质干细胞(PMSCs)治疗多种疾病正处于前沿。在此,我们讨论了关于其分离程序和表型标准化的最新发现,以及使用它们的优点和局限性。我们还讨论了胎盘细胞产品的安全性,包括PMSCs的衰老和诱变问题,以及临床前研究的疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验